AbCellera Biologics Q2 EPS $(0.13) Beats $(0.14) Estimate, Sales $7.32M Miss $10.15M Estimate
Portfolio Pulse from Benzinga Newsdesk
AbCellera Biologics (NASDAQ:ABCL) reported Q2 EPS of $(0.13), beating the $(0.14) estimate, but missed sales estimates with $7.32M against $10.15M. EPS improved by 7.14% YoY, but sales decreased by 27.18%.
August 06, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AbCellera Biologics reported Q2 EPS of $(0.13), beating the $(0.14) estimate, but missed sales estimates with $7.32M against $10.15M. EPS improved by 7.14% YoY, but sales decreased by 27.18%.
While AbCellera Biologics beat EPS estimates, the significant miss on sales and the YoY decline in both EPS and sales could create mixed reactions in the market. Investors may be concerned about the sales decline, but the EPS beat might provide some reassurance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100